Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares. With key initiatives progressing on track, the firm looks forward to the final NHP FVIII durability analysis in the first half of 2025 as well as updates on Ionis (IONS) collaboration programs and preclinical PoC for a secreted protein deficiency target this year.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX: